[Preprint] Open-label RCT: Baricitinib noninferior to Tocilizumab in hospitalized patients with severe COVID-19.

Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial – medRxiv

Related:

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial – The Lancet Respiratory Medicine

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis – medRxiv

WHO recommends two new drugs to treat COVID-19 – World Health Organization

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial – The Lancet Respiratory Medicine

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 – New England Journal of Medicine

Commentary on Twitter

Preprint⚡⚡
Baricitinib Vs Tocilizumab open label RCT
Baricitinib was non-inferior to tocilizumab with regards to the composite outcome of mechanical ventilation or death by day 28 and the time to discharge by day 28 in patients with severe #COVID19 https://t.co/sQkhATkjEd

— Antibiotic Steward Bassam Ghanem?? (@ABsteward) June 16, 2022